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Abstract
The concept that vegetables and fruits are relevant sources of cancer-preventive substances is strongly supported
by population studies. Among others, cruciferous vegetables like broccoli, cabbage, cauliflower and Brussels sprouts
are thought to affect the development of various types of cancers and especially prostate tumors. Yet, the identifi-
cation of the molecular mechanisms by which the ‘active’ compounds contained in these vegetables mediate their
anticancer activity has historically lagged behind. Accordingly, direct laboratory evidence of how individual nutri-
ents affect cancer genes and the pathways they control remains the major obstacle to progress in this research
field. Here we review a recent report investigating the interaction between sulforaphane, a dietary isothiocyanate
derived from broccoli, and expression of the PTEN tumor suppressor gene in pre malignant prostate tissue.
Introduction
The rationale for consuming fruit and vegetables to pre-
vent cancer is that edible plants contain specific com-
pounds or mixtures of compounds capable to reverse,
suppress, prevent or delay either the initial phase of car-
cinogenesis or the progression of neoplastic cells to can-
cer [1]. This culture has been amply validated by
epidemiological studies, with many intestinal cancers
being currently considered as the result of a “non-defi-
ciency malnutrition”. However, little is still known on
the mechanism(s) by which phytonutrients prevent can-
cer, and attempts to translate clinically the results of
epidemiological-, cellular-, and animal studies on dietary
chemopreventive compounds have so far met with lim-
ited success or with downright failure [2]. Indeed, the
divide between dietary and clinical studies on cancer
prevention has grown steadily. On the one hand, the
awareness that fruit and vegetables are associated to a
reduced incidence of cancer is well rooted, but, at the
same time, there is also a wide acceptance of the skeptic
and almost non-scientific view that nutrition is too com-
plex to be summarized into molecular mechanisms of
health promotion by single constituents [3]. Add also
the commercial stakes from the food industry to pro-
mote the healthy properties of products enriched with
ingredients that consumers can perceive as “cancer pre-
venting”, and the picture could not be more confused
and confusing.
Indeed, the study of dietary phytonutrients is compli-
cated. By definition, unlike vitamins and minerals, they
are non-essential, with huge differences in individual
sensibility to their biological activity. As a result, their
beneficial (or detrimental) health effects are statistical in
nature and can be observed only in population studies.
Furthermore, the concentration of phytonutrients in
food is dramatically altered by culinary processing (peal-
ing, heating, freezing) and by a set of nuances not unlike
those that make it possible for wine connoisseurs to dis-
tinguish a cheap wine from a precious crue (plant vari-
ety, terroir, harvesting time, processing, storing). Finally,
many dietary compounds are extensively modified by
phase 1 and phase 2 metabolisms, and are not present
in humans in their natural form, but only as metabo-
lites. Laboratory studies have demonstrated chemopre-
ventive activity for several phytonutrients, and especially
anthocyanins from berries, procyanidins from grape
seeds, phytoestrogens from soy, isothiocyanates from
cruciferous plants, epigallocatechin gallate from tea, cur-
cumin from turmeric, and resveratrol from wine [4].
These compounds can modulate gene expression
involved in the regulation of cell proliferation, differen-
tiation, and apoptosis, as well as in the suppression of
metastasis and angiogenesis. Evidence of clinical activity
based on the monitoring of precise biomarkers has been
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respect to colon cancer.
Sulforafane from broccoli is the best known chemo-
preventive isothiocyanate. It is formed from a glucosino-
late precursor by enzymatic hydrolysis followed by
spontaneous Lossen rearrangement. The enzyme
involved (myrosinase) is inactivated by heating, but is
expressed also by intestinal bacteria, so that also culin-
ary processed broccoli maintain at least part of their
chemopreventive potential.
Multiple epidemiological, mouse models and cell
based studies indicate that broccoli-derived Sulforafane
may affect the development of various types of cancers
and especially prostate tumors.
Discussion
So far the definition of the molecular mechanism(s)
linking the consumption of Sulforafane to its antitu-
moral effects has been lacking. In a recently published
work Traka and colleagues [5] tackled this important
issue.
T h e i ra n a l y s i si sc e n t e r e do nh o wS Fa f f e c t st h e
expression profiles of tissues in relationship to the pre-
sence of the tumor suppressor PTEN gene. PTEN is a
phosphatase playing an antagonist role in the phosphati-
dylinositol-3-kinase (PI3K/AKT) signaling pathway that
controls among other biological outputs cell growth and
apoptosis [6].
Why analyze the impact of SF on PTEN expression?
The choice is based on a solid rationale: deletion of the
PTEN gene is one of the early initiating events leading
to prostatic intraepithelial neoplasia (PIN), and subse-
quently to cancer. Analyses from patients’ samples indi-
cate that PTEN alterations occur very frequently in
human prostate cancer tissues [7]. There is also conclu-
sive evidence that deletion of PTEN results in early
onset of mPIN and subsequent development of prostate
cancer in multiple mouse models. For their studies
Traka and colleagues used the PTENL/L;PB-Cre4 mouse
model [8]. In this mouse strain CRE-mediated inactiva-
t i o no ft h eP T E Nl o c u sa l l o w st h eo c c u r r e n c eo fP T E N
deficient (’null’) and wild type (WT) PTEN mice within
the same litter. Once they reach the age of eight-weeks
of age, pAKT is highly expressed in all epithelial pro-
static cells of these mice, with most glands exhibiting
mPIN.
Interestingly, the authors found that modulation of the
dietary intake of SF in these mice had no effect on gene
expression in mouse prostate tissue with PTEN expres-
sion, whereas in isogenic PTEN deficient tissues SF
reduced PTEN deletion-mediated gene expression and
induced additional changes in gene expression.
The molecular profile associated with SF treatment
was highly complex and affected multiple genes involved
in cell cycle arrest and apoptosis. Importantly the
authors went on to show that the signature was at least
partially overlapping with previously reported changes in
human prostate tissue following diets enriched in broc-
coli (a dietary source of SF). Finally they provide preli-
minary evidences that the interaction between PTEN
deletion and supplementation of diet with SF can result
in the alternative splicing of many genes.
These tantalizing results also have drawbacks. For
example, while clearly affecting the PTEN null driven
transcriptional profile, SF nevertheless failed to signifi-
cantly impact tumor progression as the histopathological
changes induced by the knock out of PTEN were unaf-
fected by SF. Also, it remains to be determined if the
effects of SF on the expression profile of PTEN null
cells are specific. For example whether SF also affects
the transcriptional profile associated with inactivation of
other tumor suppressor genes (such as p53) or activa-
tion of classical oncogenes (such as KRAS) remains to
be shown. In other words rather then being PTEN-spe-
cific the effect of SF on transcription might be due to a
general ‘tumorigenic drift’ of the targeted cells. Also of
note, the effects of SF on exon splicing events was only
measured in the mouse models, whether a diet rich in
SF will have the same impact on human prostate tissues
remains to be tested.
Even considering the above caveats, these results are
relevant. The main reason is that they provide evidences
of an alleged molecular mechanism linking the impact
of a dietary component to tumor onset. As noted above,
a key historical skepticism faced by the field of cancer
prevention has been the lack of mechanistic evidence
that natural compounds indeed affected the established
cancer genes and the pathways they control. In this
regard the work of Traka and colleagues represents a
significant step forward as it provides a number of ‘tes-
table’ hypotheses to draft molecular links between con-
sumption of edible plants (containing specific
compounds or mixtures of compounds) and the well
accepted theory of cancer being ‘in essence’ a genetic
disease.
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